



FOR IMMEDIATE RELEASE

July 19, 2006 Boca Raton, FL:

Contact:

Larry J. Lapila
Vice President
Business Development
info@bpirx.com

Breckenridge Pharmaceutical, Inc. announced that they received FDA Approval to market Meloxicam 7.5mg and 15mg tablets. Meloxicam tablets are AB rated to Mobic®, a \$1 billion brand name arthritis drug, by Boehringer Ingelheim. Breckenridge shipped product to its customers the day it was approved.

“We were pleased to be approved in the first group of ANDA’s, and to have shipped all of our orders the same day,” said Larry J. Lapila, Vice President of Business Development. This is the first ANDA approved in the Breckenridge name. Breckenridge has over a dozen ANDA’s in its development program including several filed and pending FDA approval.

Breckenridge is actively seeking development and marketing alliances with domestic and foreign companies for generic and branded pharmaceuticals.

Breckenridge products are contract manufactured through partnerships with pharmaceutical manufacturers in state-of-the-art plants throughout the U.S. Breckenridge maintains a stringent Quality Assurance program to ensure a consistent supply of quality pharmaceutical products.

About Breckenridge:

Breckenridge Pharmaceutical, Inc., a privately-held pharmaceutical marketing research and development company founded in 1983, is headquartered in Boca Raton, FL, with offices in Berlin, CT, and Fairfield, NJ. Breckenridge markets over 100 products in many therapeutic categories to over 100 customers in all classes of trade.

Mobic® is a registered trademark of Boehringer Ingelheim.

Corporate Office: 1141 S. Rogers Circle, Suite 3 • Boca Raton, FL 33487 • Phone: (561) 443-3314 • Fax: (561) 989-9747
CT Office: 15 Massirio Drive, Suite 201 • Berlin, CT 06037 • Phone: (860) 828-8140 • Fax: (860) 828-8142
New Jersey Office: 1 Passaic Avenue • Fairfield, NJ 07004 • Phone: (973) 808-6899 • Fax: (973) 808-9719